Olema director granted 29,500 stock options

Olema Pharmaceuticals director Gorjan Hrustanovic received a grant of stock options for 29,500 shares of common stock at an exercise price of $9.51 per share.

Rhea-AI Filing Summary

Olema Pharmaceuticals director Gorjan Hrustanovic received a grant of stock options for 29,500 shares of common stock at an exercise price of $9.51 per share. The options expire on June 18, 2036 and vest in 12 equal monthly installments starting June 18, 2026, with any remaining unvested portion vesting in full on the date of Olema’s next annual stockholder meeting if not already fully vested, subject to his continued service. Under a pre-existing arrangement, any economic benefit from the sale of shares issued upon exercise is payable to BVF Partners L.P., and Hrustanovic disclaims beneficial ownership except for any pecuniary interest.

Insider Trade Summary

Grant/Award: 29,500 shares

Grant/Award 1 txn

Insider Hrustanovic Gorjan

Role Director

Type	Security	Shares	Price	Value
Grant/Award	Stock Option (right to buy)	29,500	$0.00	$0.00

Holdings After Transaction: Stock Option (right to buy) — 29,500 contracts (Direct)

Footnotes (2)

1. F1. The shares subject to the option vest in a series of 12 successive equal monthly installments measured from June 18, 2026, subject to the Reporting Person's continuous service through each applicable vesting date. Such shares vest in full on the date of the Issuer's next annual meeting of stockholders if such stock option is not otherwise fully vested by such date, subject to the Reporting Person's continuous service through such vesting date.
2. F2. The Reporting Person is a member of BVF Partners L.P. ("BVF") and is obligated to transfer the economic benefit, if any, received upon the sale of the shares issuable upon exercise of the equity grants to BVF. As such, the Reporting Person disclaims beneficial ownership of the securities reported herein for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, except to the extent of his pecuniary interest therein, if any.

Key Figures

Option grant size: 29,500 options Exercise price: $9.51 per share Expiration date: June 18, 2036 +3 more

6 metrics

Option grant size 29,500 options Stock Option (right to buy) granted to director

Exercise price $9.51 per share Strike price for Olema common stock under options

Expiration date June 18, 2036 Option term end for the grant

Vesting schedule 12 equal monthly installments Measured from June 18, 2026, subject to continuous service

Alternative vesting trigger Full vesting by next annual meeting If not fully vested earlier and with continued service

Shares underlying options 29,500 shares Olema common stock issuable upon exercise

Key Terms

Stock Option (right to buy), beneficial ownership, pecuniary interest, Section 16 of the Securities Exchange Act of 1934, +1 more

5 terms

Stock Option (right to buy) financial

"security_title: Stock Option (right to buy)"

beneficial ownership regulatory

"the Reporting Person disclaims beneficial ownership of the securities reported herein"

Beneficial ownership means the person or entity that actually enjoys the benefits of owning shares or other assets — such as receiving dividends, voting rights, or price gains — even if the legal title is held in another name. For investors it matters because knowing who truly controls and profits from a company reveals who can influence decisions, exposes potential conflicts of interest or hidden concentration of power, and affects transparency and risk in the stock.

pecuniary interest financial

"except to the extent of his pecuniary interest therein, if any"

Section 16 of the Securities Exchange Act of 1934 regulatory

"for purposes of Section 16 of the Securities Exchange Act of 1934, as amended"

A provision of federal securities law that requires company insiders—directors, officers and large shareholders—to publicly report their stock holdings and trades and to surrender any “short-swing” profits from purchases and sales within a six-month window. It acts like a rule that forces leaders to announce their trades and prevents quick buy-sell windfalls, giving investors transparency into insider activity and reducing opportunities for unfair gain.

continuous service financial

"subject to the Reporting Person's continuous service through each applicable vesting date"

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What did Olema Pharmaceuticals (OLMA) director Gorjan Hrustanovic receive in this Form 4 filing?

He received a grant of stock options for 29,500 shares of Olema common stock at a $9.51 exercise price. These options are a compensation award, not an open-market stock purchase or sale, and provide potential future ownership if exercised.

What are the key terms of Gorjan Hrustanovic’s Olema (OLMA) stock option grant?

The grant covers 29,500 options to buy Olema common stock at $9.51 per share, expiring June 18, 2036. The options vest over time, giving him the right, but not the obligation, to purchase shares at this fixed price if exercised.

How do the Olema (OLMA) stock options granted to Gorjan Hrustanovic vest over time?

The options vest in 12 equal monthly installments starting June 18, 2026, conditioned on continued service. Any remaining unvested options vest in full on the date of Olema’s next annual stockholder meeting if they are not already fully vested by that time.

Who ultimately benefits economically from Gorjan Hrustanovic’s Olema (OLMA) option grant?

Hrustanovic is obligated to transfer any economic benefit from selling shares issued on exercise to BVF Partners L.P. He therefore disclaims beneficial ownership of these securities, except to the extent of any pecuniary interest he may have through this arrangement.

Does this Olema (OLMA) Form 4 show an insider buying or selling shares on the market?

No, it reports a compensatory stock option grant rather than an open-market transaction. Hrustanovic acquired derivative rights to buy 29,500 shares at $9.51, but no common shares were bought or sold in the market in this specific filing.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 06/23/2026 - 05:27 PM EDT Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Hrustanovic Gorjan

(Last) (First) (Middle)

C/O OLEMA PHARMACEUTICALS, INC.

780 BRANNAN ST

(Street)

SAN FRANCISCO CALIFORNIA 94103

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Olema Pharmaceuticals, Inc. [ OLMA ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
06/18/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (right to buy)	$9.51	06/18/2026		A		29,500		(1)	06/18/2036	Common Stock	29,500	$0	29,500	D(2)

Explanation of Responses:

1. The shares subject to the option vest in a series of 12 successive equal monthly installments measured from June 18, 2026, subject to the Reporting Person's continuous service through each applicable vesting date. Such shares vest in full on the date of the Issuer's next annual meeting of stockholders if such stock option is not otherwise fully vested by such date, subject to the Reporting Person's continuous service through such vesting date.

2. The Reporting Person is a member of BVF Partners L.P. ("BVF") and is obligated to transfer the economic benefit, if any, received upon the sale of the shares issuable upon exercise of the equity grants to BVF. As such, the Reporting Person disclaims beneficial ownership of the securities reported herein for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, except to the extent of his pecuniary interest therein, if any.

	/s/ Shawnte Mitchell, Attorney-in-Fact	06/23/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)